Anas Younes, Senior Vice President, Head of Haematology R&D, at AstraZeneca, discusses building a broad portfolio to target different hematological cancers through diverse mechanisms and modalities, such as the next wave of IO therapies and apoptotic pathway modulating agents and his vision to develop future cornerstones for novel combination treatment strategies in hematological cancers.
“In my role, I lead AstraZeneca’s new Haematology R&D unit, with responsibilities spanning from early discoveries and target identification, to first-in-human clinical studies, to late stage trials and drug approvals.
I am a clinician-scientist and have spent more than 25 years caring for patients with lymphoma. Prior to joining AstraZeneca, I was at Memorial Sloan Kettering Cancer Center (MSKCC) where I served as the Chief of the Lymphoma Service, in addition to leading a laboratory focused on drug development for patients with lymphoid malignancies. Our lab was focused on accelerating the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Prior to MSKCC, I worked for 20 years at University of Texas MD Anderson Cancer Center (MDACC) where I directed clinical and translational research in the Department of Lymphoma and Myeloma.”